Dogwood Therapeutics Inc
DWTX
Company Profile
Business description
Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.
Contact
44 Milton Avenue
AlpharettaGA30009
USAT: +1 866 620-8655
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
12
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,035.50 | 16.90 | 0.19% |
| CAC 40 | 8,121.07 | 0.00 | 0.00% |
| DAX 40 | 24,283.97 | 4.43 | -0.02% |
| Dow JONES (US) | 48,362.68 | 227.79 | 0.47% |
| FTSE 100 | 9,865.97 | 31.45 | -0.32% |
| HKSE | 25,801.77 | 111.24 | 0.43% |
| NASDAQ | 23,428.83 | 121.21 | 0.52% |
| Nikkei 225 | 50,485.11 | 82.72 | 0.16% |
| NZX 50 Index | 13,509.63 | 1.33 | 0.01% |
| S&P 500 | 6,878.49 | 43.99 | 0.64% |
| S&P/ASX 200 | 8,735.90 | 19.00 | 0.22% |
| SSE Composite Index | 3,917.36 | 26.92 | 0.69% |